Provider Briefing: Azithromycin Supply in 2026

Azithromycin remains one of the most frequently prescribed antibiotics in the United States, with over 40 million prescriptions filled annually. As a frontline treatment for community-acquired pneumonia, acute exacerbations of COPD, sexually transmitted infections, and numerous other bacterial conditions, supply disruptions have direct clinical implications.

This briefing provides an overview of the current Azithromycin supply situation, affected formulations, prescribing considerations, and resources to help your patients access their medications.

Shortage Timeline

The current Azithromycin supply disruption has unfolded in stages:

• 2020-2021: COVID-19 pandemic drives massive demand surge for Azithromycin due to off-label prescribing. Stockpiles depleted, production schedules disrupted across multiple manufacturers.
• 2022-2023: Supply gradually normalizes for tablet formulations. Some manufacturers reduce production capacity for niche formulations based on post-pandemic demand recalibration.
• May 2024: Mylan (Viatris) discontinues Azithromycin oral powder for suspension in 1-gram packets.
• July 2025: Pfizer discontinues brand-name Zithromax oral powder for suspension 1-gram packets (3-count), leaving no manufacturers for this specific formulation.
• 2026 (current): ASHP lists Azithromycin oral suspension 1-gram packets as currently in shortage. Tablets and standard oral suspension bottles remain in adequate supply.

Prescribing Implications

The shortage primarily affects the 1-gram oral suspension powder packets, which are commonly used for:

• Single-dose Chlamydia treatment: The 1-gram single dose has been a standard regimen for uncomplicated C. trachomatis infections
• Single-dose STI treatments in clinic settings where directly observed therapy is preferred
• Patients who cannot swallow tablets

Recommended Prescribing Adjustments

For most patients, the 1-gram dose can be achieved through alternative formulations:

• Four 250 mg tablets taken simultaneously — widely available and therapeutically equivalent
• Two 500 mg tablets taken simultaneously — same total dose
• Standard oral suspension bottles (200 mg/5 mL) dosed at 25 mL for a 1-gram dose — available for patients who cannot take tablets

For STI indications specifically, the CDC's 2021 STI Treatment Guidelines already note Doxycycline 100 mg twice daily for 7 days as the preferred regimen for uncomplicated chlamydial infections, with Azithromycin 1 gram as an alternative. Consider whether Doxycycline may be the more appropriate first-line choice given current availability.

Current Availability Picture

Cost and Access Considerations

Azithromycin remains highly affordable, which benefits patient adherence:

• Generic Z-Pak (six 250 mg tablets): $10-$36 cash price; as low as $4-$10 with discount coupons
• Insurance coverage: Universally covered as Tier 1 preferred generic across commercial, Medicare Part D, and Medicaid plans
• No prior authorization typically required
• No step therapy requirements for most plans

For patients facing financial barriers, free discount programs from GoodRx, SingleCare, and pharmacy-specific programs (Walmart $4 list) can reduce costs significantly. Learn more about patient savings resources in our provider's guide to helping patients save on Azithromycin.

Tools and Resources for Providers

Medfinder for Providers

Medfinder allows providers and clinical staff to check real-time pharmacy availability for Azithromycin and other medications. This can be especially helpful when:

• Patients report difficulty filling prescriptions
• Your practice needs to identify in-stock pharmacies for same-day treatment
• You're managing STI cases requiring directly observed therapy and need to locate the appropriate formulation quickly

ASHP Drug Shortage Resources

Monitor the ASHP Drug Shortages page for updated information on Azithromycin and other medications in shortage.

Clinical Alternatives Quick Reference

When Azithromycin is unavailable or clinically inappropriate:

• Community-acquired pneumonia: Doxycycline, Amoxicillin, respiratory fluoroquinolones (Levofloxacin, Moxifloxacin)
• Chlamydia: Doxycycline 100 mg BID x 7 days (preferred per CDC guidelines)
• Acute sinusitis: Amoxicillin-Clavulanate, Doxycycline
• Acute otitis media: Amoxicillin (first-line), Amoxicillin-Clavulanate
• MAC prophylaxis: Clarithromycin

For more detailed alternative options, see our Azithromycin alternatives guide.

Looking Ahead

The tablet and standard suspension supply for Azithromycin appears stable heading into the remainder of 2026. The 1-gram packet shortage is unlikely to resolve unless a new manufacturer enters the market, which could take 12-18 months given FDA approval timelines for generic formulations.

Providers should plan for continued unavailability of the 1-gram packets and update clinical protocols accordingly — particularly for STI clinics and settings that rely on single-dose directly observed therapy.

Final Thoughts

Azithromycin remains a critical tool in infectious disease management. While the tablet shortage fears from the pandemic era have subsided, the 1-gram packet discontinuation presents a real — though manageable — clinical challenge. By adjusting prescribing patterns and leveraging tools like Medfinder for Providers, you can continue to ensure your patients get the treatment they need.

For patient-facing resources you can share, see our guides on finding Azithromycin in stock and Azithromycin side effects.